PL2219451T3 - Sposób leczenia nowotworów tkanek krwiotwórczych - Google Patents

Sposób leczenia nowotworów tkanek krwiotwórczych

Info

Publication number
PL2219451T3
PL2219451T3 PL08851754T PL08851754T PL2219451T3 PL 2219451 T3 PL2219451 T3 PL 2219451T3 PL 08851754 T PL08851754 T PL 08851754T PL 08851754 T PL08851754 T PL 08851754T PL 2219451 T3 PL2219451 T3 PL 2219451T3
Authority
PL
Poland
Prior art keywords
hematopoietic neoplasms
treating hematopoietic
treating
neoplasms
hematopoietic
Prior art date
Application number
PL08851754T
Other languages
English (en)
Inventor
David Chaplin
Bronwyn G Siim
Original Assignee
Oxigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene Inc filed Critical Oxigene Inc
Publication of PL2219451T3 publication Critical patent/PL2219451T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL08851754T 2007-11-21 2008-11-21 Sposób leczenia nowotworów tkanek krwiotwórczych PL2219451T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98978607P 2007-11-21 2007-11-21
PCT/US2008/084427 WO2009067706A1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms
EP08851754.5A EP2219451B1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms

Publications (1)

Publication Number Publication Date
PL2219451T3 true PL2219451T3 (pl) 2015-04-30

Family

ID=40667883

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08851754T PL2219451T3 (pl) 2007-11-21 2008-11-21 Sposób leczenia nowotworów tkanek krwiotwórczych

Country Status (12)

Country Link
US (4) US20090192098A1 (pl)
EP (1) EP2219451B1 (pl)
JP (1) JP5302328B2 (pl)
AU (1) AU2008326251B2 (pl)
CA (1) CA2703283C (pl)
DK (1) DK2219451T3 (pl)
ES (1) ES2529434T3 (pl)
HR (1) HRP20150040T1 (pl)
PL (1) PL2219451T3 (pl)
PT (1) PT2219451E (pl)
SI (1) SI2219451T1 (pl)
WO (1) WO2009067706A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478288A1 (en) * 2002-03-07 2003-09-12 Adrian Woolfson Scd fingerprints
WO2009067706A1 (en) 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
CN111447972A (zh) * 2017-10-25 2020-07-24 生态学有限公司 治疗急性髓系白血病的方法
JP7428717B2 (ja) * 2019-01-15 2024-02-06 ピーティーシー セラピューティクス， インコーポレイテッド 急性骨髄性白血病の治療方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
AU741382B2 (en) 1997-03-26 2001-11-29 Large Scale Biology Corporation Di-aryl ethers and their derivatives as anti-cancer agents
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999035150A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f
US6943194B1 (en) 1998-01-09 2005-09-13 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
IL138572A0 (en) 1998-03-25 2001-10-31 Biosource Genetics Corp Benzoate derivatives and pharmaceutical compositions containing the same
US6433012B1 (en) 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
DE69931766T2 (de) 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
WO2000006556A1 (en) 1998-07-27 2000-02-10 Abbott Laboratories Substituted oxazolines as antiproliferative agents
WO2000035865A2 (en) 1998-12-17 2000-06-22 Tularik Inc. Tubulin-binding agents
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
EP2289521A3 (en) 1999-02-18 2011-10-05 Arizona Board Of Regents Compositions and methods for use in tergeting vascular destruction
CO5170498A1 (es) 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US6201001B1 (en) 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
GB9918912D0 (en) 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
DE60129536T2 (de) * 2000-03-10 2008-06-19 Baylor University, Waco Tubulin bindende liganden
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
CA2407672A1 (en) 2000-04-27 2001-11-01 Matthew P. Grealish Hydroxyphenstatin and the prodrugs thereof
CA2407675C (en) * 2000-04-27 2012-07-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Combretastatin a-1 phosphate and combretastatin b-1 phosphate prodrugs
US20040122083A1 (en) 2000-05-09 2004-06-24 Pettit George R Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
NZ522767A (en) * 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
AU2001296215A1 (en) * 2000-07-17 2002-01-30 Oxi-Gene, Inc. Efficient method of synthesizing combretastatin a-4 prodrugs
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
AU2002216228A1 (en) 2000-12-21 2002-07-01 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US7037906B1 (en) 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
GB2377469B (en) 2001-07-13 2005-07-06 Prismo Ltd Method and apparatus for laying a traffic calming surface
JP2005507912A (ja) 2001-10-26 2005-03-24 オキシジーン， インコーポレイテッド 改良型血管標的化剤としての官能化スチルベン誘導体
GB0126889D0 (en) 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
WO2003059855A1 (en) 2001-12-21 2003-07-24 Arizona Board Of Regents Synthesis of combretastatin a-2 prodrugs
US7125906B2 (en) 2002-04-03 2006-10-24 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20040024696A1 (en) 2002-08-02 2004-02-05 Federico Alves System for automatically transferring funds
TW549690U (en) 2002-11-13 2003-08-21 Tekcon Electronics Corp Electrical card connector
WO2004078126A2 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
US7429681B2 (en) 2005-06-14 2008-09-30 Baylor University Combretastatin analogs with tubulin binding activity
WO2009067706A1 (en) 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms

Also Published As

Publication number Publication date
DK2219451T3 (en) 2015-01-12
US20090192098A1 (en) 2009-07-30
AU2008326251B2 (en) 2014-03-06
US20120270831A1 (en) 2012-10-25
HRP20150040T1 (hr) 2015-02-27
AU2008326251A1 (en) 2009-05-28
US20150246064A1 (en) 2015-09-03
EP2219451A4 (en) 2011-01-19
EP2219451A1 (en) 2010-08-25
CA2703283A1 (en) 2009-05-28
EP2219451B1 (en) 2014-11-12
JP5302328B2 (ja) 2013-10-02
US9040500B2 (en) 2015-05-26
PT2219451E (pt) 2015-02-09
CA2703283C (en) 2016-01-12
JP2011504510A (ja) 2011-02-10
WO2009067706A1 (en) 2009-05-28
US20090264382A1 (en) 2009-10-22
SI2219451T1 (sl) 2015-02-27
ES2529434T3 (es) 2015-02-20

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
IL209895A0 (en) Compounds for treating beta-amyloidoses
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
ZA201001753B (en) Method for consumer-dispenser interactions
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
PT2361116T (pt) Aparelho de irradiação
PL2376410T3 (pl) Sposób suszenia
IL209894A0 (en) Compounds for treating amyloidoses
GB0803107D0 (en) Method
IL213476A0 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
PL2301893T3 (pl) Sposób oczyszczania ścieku
IL208069A0 (en) Methods for treating psoriasis
IL210097A0 (en) Compositions and methods for treating unfluenza
IL213398A0 (en) Compounds for treating cancer
GB0806792D0 (en) Co-Existence method
IL199739A0 (en) Methods for treating psoriasis
GB0804981D0 (en) Method
PL2376597T3 (pl) Proces obróbki odpadów
GB0807409D0 (en) Method
GB0804690D0 (en) Method
IL212212A0 (en) Compound useful for treating cellulite
PT2219451E (pt) Processo para o tratamento de neoplasmas hematopoiéticos
EP2144888A4 (en) METHODS OF TREATING CANCER
EP2321435A4 (en) WIEDERAUFKOHLUNGSVERFAHREN
GB0805862D0 (en) Method